{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Therapy",
    "query": {
      "condition": "Genetic Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2422,
    "total_pages": 243,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T03:46:00.901Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00937794",
      "title": "Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hunter Syndrome"
      ],
      "interventions": [
        {
          "name": "Neurobehavioral testing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Visual and auditory assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "32 Months",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "32 Months to 18 Years · Male only"
      },
      "enrollment_count": 33,
      "start_date": "2009-07-02",
      "completion_date": "2011-07-13",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00937794"
    },
    {
      "nct_id": "NCT02006472",
      "title": "A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "Pridopidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Prilenia",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 408,
      "start_date": "2014-02-28",
      "completion_date": "2016-07-07",
      "has_results": true,
      "last_update_posted_date": "2021-07-19",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 16,
      "location_summary": "La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02006472"
    },
    {
      "nct_id": "NCT02904772",
      "title": "Alipogene Tiparvovec for the Treatment of LPLD Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "LPL Deficiency"
      ],
      "interventions": [
        {
          "name": "alipogene tiparvovec",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporins",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UniQure Biopharma B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-10",
      "completion_date": "2020-09",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02904772"
    },
    {
      "nct_id": "NCT03219164",
      "title": "Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization",
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "AZLI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 149,
      "start_date": "2017-11-28",
      "completion_date": "2021-09-23",
      "has_results": true,
      "last_update_posted_date": "2022-06-14",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 12,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219164"
    },
    {
      "nct_id": "NCT01253733",
      "title": "MD2Me - Texting to Promote Chronic Disease Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Inflammatory Bowel Disease",
        "Type 1 Diabetes",
        "Chronic Disease Management"
      ],
      "interventions": [
        {
          "name": "MD2ME",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Huang, Jeannie, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "14 Years to 22 Years"
      },
      "enrollment_count": 81,
      "start_date": "2009-10",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2016-01-26",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01253733"
    },
    {
      "nct_id": "NCT01457430",
      "title": "Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Icatibant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2011-12",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-10-18",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wheaton",
          "state": "Maryland"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01457430"
    },
    {
      "nct_id": "NCT00754052",
      "title": "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Down Syndrome",
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "Aricept (donepezil hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "11 Years to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-09",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-23",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas • Herndon, Virginia",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Herndon",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00754052"
    },
    {
      "nct_id": "NCT01650948",
      "title": "Genetic Load and Phenotype in Aggressive AMD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RetnaGene AMD LDT",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Sequenom, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Lexington, Kentucky • Nashville, Tennessee",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01650948"
    },
    {
      "nct_id": "NCT02855476",
      "title": "HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University College, London",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "11 Years to 75 Years"
      },
      "enrollment_count": 2500,
      "start_date": "2017-01-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 6,
      "location_summary": "Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02855476"
    },
    {
      "nct_id": "NCT05462106",
      "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyloid Plaque",
        "Beta-Amyloid",
        "DSAD",
        "Prodromal Alzheimer's Disease",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo (Study Part 1a)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose A in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose B in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 at Dose C in Study Part 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Study Part 1b)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AC Immune SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 304,
      "start_date": "2022-06-21",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-07T03:46:00.901Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lady Lake",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05462106"
    }
  ]
}